
Overview
I mainly treat patients with genitourinary cancers including prostate, kidney, bladder, testicular and penile cancer. My goal is to be attentive and devoted to my patients who are often dealing with complicated health problems. I try to personalize my care because every patient is different. I believe the future is promising because new treatments are being discovered every day. I am involved in clinical trials done through Duke University. Clinical trials are designed to provide patients with access to the newest possible treatments. I am also part of our multi-disciplinary cancer team including urologic oncologists, geneticists, radiation oncologists, pathologists, radiologists, and other specialists. I grew up in Cary and did all of my medical training in the Research Triangle Park area. I feel honored to practice in the same community I have lived in for more than twenty-five years.
Dr. Ramalingam is rated as an Experienced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Muscle Invasive Bladder Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Multiple Myeloma.
His clinical research consists of co-authoring 18 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE MAPD
- MEDICARE SNP
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- MEDICARE MAPD
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- HMO
- POS
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- OTHER COMMERCIAL
- PPO
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
216 Ashville Ave, Cary, NC 27518
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
UT MD Anderson Cancer Center
Guilin Tang is a Hematologist in Cary, North Carolina. Dr. Tang is rated as an Elite provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft.
Duke Blood Cancer Center
I have the privilege of caring for patients with various myeloproliferative neoplasms including, polycythemia vera, essential thrombocytosis, primary myelofibrosis, systemic mastocytosis, and chronic myeloid leukemia. My goal is to provide the best possible care for each individual patient in an era where the number of therapeutic options for patients with myeloproliferative neoplasms is rapidly expanding. As a clinical investigator leading several clinical studies in both early and late stages of development, I strive to offer patients access to investigational agents with novel mechanisms of action via participation in clinical trials. I believe that every patient has a unique diagnosis and personal experience with their cancer. I aim to consider the disease, the patient and individual care goals in partnering with patients to develop and implement personalized treatment plans. Dr. Rein is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Systemic Mastocytosis, Myelofibrosis, Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.
Duke Blood Cancer Center
I entered medical school for the sole purpose of learning more about human diseases, so that I could focus my laboratory efforts on improving the human condition. However, I was surprised to find myself drawn to clinical care. I care for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, I have had the privilege of treating people facing life-threatening illnesses. I strive to gain the trust of each of my patients, so that I can help them make difficult treatment decisions. I engage in clinical research, evaluating novel agents that directly target the cancer cell to improve the degree of success in treating this illness. My patients benefit from my understanding of the newest available treatments, and also have access to promising investigational agents, when appropriate. In my faculty position at Duke University, I enjoy educating current oncologists as well as the next generation of physicians. Dr. Erba is rated as an Elite provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Muscle Invasive Bladder CancerDr. Ramalingam isDistinguished. Learn about Muscle Invasive Bladder Cancer.
- Upper Tract Urothelial Carcinoma (UTUC)Dr. Ramalingam isDistinguished. Learn about Upper Tract Urothelial Carcinoma (UTUC).
- Advanced
- Adult T-Cell LeukemiaDr. Ramalingam isAdvanced. Learn about Adult T-Cell Leukemia.
- Chronic T-Cell Leukemia (CTCL)Dr. Ramalingam isAdvanced. Learn about Chronic T-Cell Leukemia (CTCL).
- Large-Cell Immunoblastic LymphomaDr. Ramalingam isAdvanced. Learn about Large-Cell Immunoblastic Lymphoma.
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Multiple MyelomaDr. Ramalingam isAdvanced. Learn about Multiple Myeloma.
- Non-Muscle Invasive Bladder CancerDr. Ramalingam isAdvanced. Learn about Non-Muscle Invasive Bladder Cancer.
- Experienced
- Adult Immune ThrombocytopeniaDr. Ramalingam isExperienced. Learn about Adult Immune Thrombocytopenia.
- AgranulocytosisDr. Ramalingam isExperienced. Learn about Agranulocytosis.
- ALK-Positive Non-Small Cell Lung CancerDr. Ramalingam isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- AnemiaDr. Ramalingam isExperienced. Learn about Anemia.
- Antiphospholipid SyndromeDr. Ramalingam isExperienced. Learn about Antiphospholipid Syndrome.
- Arterial EmbolismDr. Ramalingam isExperienced. Learn about Arterial Embolism.

